Anybody follow this one ?

A little antipation going on again this morning. I must say that rumours make the game rather more interestng and give us the opportunity to buy and sell making modest profit practically weekly!!.

You have all gone a little quiet this morning. As I predicted great chance to buy for the brave this morning - I did at 7.05 - well just a little !!

Oakapples,

And a well timed move it was too.

1.2M loss vs 5.46M is the bottom line which is a substantial improvement on last year.

Far too many people were expecting sparkling results in addition to an annoucement over the US distribution deal and raced for the sell button (rather prematurely in my view).

The news which will really shift the price North with huge momentum is that on the distribution deal. I'm assuming that the modest placement will act as an insurance to cover cash flow during the period between shipping products and being paid by the distributor - because there could be one hell of a load of products needed in the US.

The placing will set a stable level for the price, which looks as though it will oscillate in the range 6-7p. As soon as there's any whiff of news on distribution deals, the buyers will be back in force, and the price could well be almost doubled in a single day's trading - so keep an eye on the news. The RNS said nothing really about deals, so we can expect news tomorrow just as much as in several months.

This is a high risk/high reward share. I believe that the brave will seriously prosper in the long run. At these levels MDW is still a tremendous bargain. 50p+ is still not unlikely by this time next year.

oakapples - did you see the RNS today ?

Directors putting their hands in their pockets and stumping up loads of cash - they must know that it is going to be returned to them several times over :-)

overgrowth - roger - I have just had a call from a Professor friend in Harrogate who advises me to top up again - I confirm that insider training is not involved but I am in for a "double" with him and the Directors opening their wallets. Good luck

Good buying opportunity as you can get them for 6p when the recent placing which was taken up by the Directors and Institutions was at 6.25p.

Look good value at 6p after reading this;

Innovative UK manufacturer of high tech screening and diagnostic systems for urological disorders.

Latest Business Organisational Update

FDA approval of the Portascan applied for and subsequently granted in
December 2003.

Distribution agreements put in place in important markets across the
world.

UK sales organisation rebuilt and refocused.

New product opportunities to complement and strengthen the existing
range identified.

Satisfactory progress with the development of the quantitative point of
care PSA diagnostic system.

Financials

Interims31/10/2003.
The operating margin in the period was 32% compared with 31% in the previous
year and the benefits of tight control of overheads resulted in expenditure of
590,000, - 115,000 less than in the comparable prior year period. In summary
therefore, the operating loss, after 174,000 amortisation of goodwill (231,000
in 2002), was 641,000 compared with 689,000 for the six months to 31st October
2002.
Cash on the books was 418,000 compared to 64,000 at the same time last year. With Sales increasing the position of the company gets stronger by the day.

Technical Products Update

A joint venture with two US corporations to develop the next generation
of the one-stop diagnostic system. This product should be launched in the second
half of 2004.

The development of a disposable product to assist control of
incontinence associated with prostate conditions. This will be available mid
2004.

The development of a compact specimen collection device for prostate
biopsies. This will be available mid 2004.

Preliminary plans to extend the portable bladder scanner range into
three other pathology areas.

Forward Outlook

A recovery in UK sales is
underway and negotiations with C R Bard for up to 9 other European countries
plus the Middle East to become party to the scanner supply agreement are
progressing. Export markets were a major focus for business development in the
period and distribution agreements were signed covering Japan, South East Asia
including Australasia. Negotiations are also in progress for sales
representation in India, Korea, China and Japan (for products not already included)

Jewel In The Crown

Most importantly however, access to the huge US market will have the
most significant impact on future sales and during the period FDA approval was
sought and recently received for the portable bladder scanner. Negotiations are
now at final stage with a large US distributor in relation to this and other
products of the Group.

CEO Philip Stimpson commented after the FDA approval for the portable bladder scanner, "the company is close to signing a distribution deal with a major International healthcare group"

Directors Buys

29 January 2004 ... The Company received notification today that
Philip Stimpson, Chief Executive Officer of the Company, bought 125,000
ordinary shares in the Company at a price of 8.03 pence each on 28 January 2004.

Kevin Middis, Finance Director,
bought 60,000 ordinary shares in the Company at a price of 8.03 pence each on 28
January 2004.

Omer Karim, Non-Executive Medical
Research Director, bought 475,000 ordinary shares in the Company at a price of
8.03 pence each on 28 January 2004.
A CLEAR SIGN THAT THE MANAGEMENT ARE VERY CONFIDENT OF THE COMPANYS FUTURE

Company Website

www.mediwatch.com

Summing up the shares are around 10.2p to buy and there are circa of 23.4 million in circulation. I rate this a speculative punt and as ever if you are tempted please DYOR and remember you are responsible for your own buying and selling timing actions.

Only thing we have waited 7 months for news that was imminent back Januray

yeah cath, its pathetic but i'm still holding. bit of a medium term hold for me this one

It has even got me buying more -topped up at 6.02 to-day - based on the rather romantic idea that it cuts my loss overall

To be able to BUY under the placing price is an offer not to be missed.

"Quote me Happy" 8% up - now how about an announcement -

Stock is very illiquid so relatively low buying volumes drives the price up.

Also looks like a double bottom on the chart ;-)

this is rocketing today. at last!

Interesting, 450,000 T BUY (Single protected purchase) reported at 7.68 pence.

At 6.5p to buy this certainly looks like we are back in the buy and hold scenario.

The anticipated news still has not materialised but when it does watch for the big rise.